GPX4-IN-9
Based on 1 Customer Validation
GPX4-IN-9 (Compound A16) is a glutathione peroxidase 4 (GPX4) inhibitor that specifically targets GPX4 under both in vitro and in vivo conditions, inducing ferroptosis. GPX4-IN-9 exhibits cytotoxicity against pancreatic cancer cells and can be used in cancer research.
For research use only. We do not sell to patients.
- Purity: 99.18%
- CAS No.: 3032746-99-6
- Formula: C26H21N3O2S2
- Molecular Weight:471.59
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Covalent Screening Library
HY-L036
-
Antioxidant Compound Library
HY-L037
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Cuproptosis Compound Library
HY-L133
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Covalent Screening Library Plus
HY-L036P
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Alkyne Compound Library
HY-L258
Biological Activity
|
GPX4 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| ASPC1 | IC50 |
0.022 μM
Compound: A16
|
Antiproliferative activity against human AsPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human AsPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 38265413] |
| ASPC1 | IC50 |
14 nM
Compound: A16
|
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 38265413] |
| ASPC1 | IC50 |
26 nM
Compound: A16
|
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay
|
[PMID: 38265413] |
| ASPC1 | IC50 |
29 nM
Compound: A16
|
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs followed by compound washout by CCK-8 assay
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 72 hrs followed by compound washout by CCK-8 assay
|
[PMID: 38265413] |
| ASPC1 | IC50 |
33 nM
Compound: A16
|
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 48 hrs followed by compound washout by CCK-8 assay
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 48 hrs followed by compound washout by CCK-8 assay
|
[PMID: 38265413] |
| ASPC1 | IC50 |
37 nM
Compound: A16
|
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
|
[PMID: 38265413] |
| ASPC1 | IC50 |
62 nM
Compound: A16
|
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 24 hrs followed by compound washout by CCK-8 assay
Induction of ferroptosis in human ASPC1 cells assessed as reduction in cell viability incubated for 24 hrs followed by compound washout by CCK-8 assay
|
[PMID: 38265413] |
| BXPC-3 | IC50 |
0.02 μM
Compound: A16
|
Antiproliferative activity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 38265413] |
| CFPAC-1 | IC50 |
0.02 μM
Compound: A16
|
Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human CFPAC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 38265413] |
| HCT-116 | IC50 |
>10 nM
Compound: A16
|
Induction of ferroptosis in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Induction of ferroptosis in human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 38265413] |
| HPAF-II | IC50 |
0.02 μM
Compound: A16
|
Antiproliferative activity against human HPAF-II cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human HPAF-II cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 38265413] |
| MIA PaCa-2 | IC50 |
0.02 μM
Compound: A16
|
Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 38265413] |
| NCI-H522 | IC50 |
3 nM
Compound: A16
|
Induction of ferroptosis in human NCI-H522 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
Induction of ferroptosis in human NCI-H522 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay
|
[PMID: 38265413] |
| PANC-1 | IC50 |
0.02 μM
Compound: A16
|
Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 38265413] |
| SW1990 | IC50 |
0.02 μM
Compound: A16
|
Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Antiproliferative activity against human SW1990 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 38265413] |
Chemical Information
-
CAS No. 3032746-99-6
-
Appearance Solid
-
Molecular Weight 471.59
-
Formula C26H21N3O2S2
-
Color Off-white to light yellow
-
SMILES
O=S(C(C=C1)=CC=C1CN(C2=CC=C(C=C2)C3=NC4=C(S3)C=CC=C4)CC#C)(N(C#C)C)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 50 mg/mL (106.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.30 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tang Z, et al. Novel Covalent Probe Selectively Targeting Glutathione Peroxidase 4 In Vivo: Potential Applications in PancrTang Z, et al. Novel Covalent Probe Selectively Targeting Glutathione Peroxidase 4 In Vivo: Potential Applications in Pancreatic Cancer Therapy. J Med Chem. 2024 Feb 8;67(3):1872-1887.eatic Cancer Therapy. J Med Chem. 2024 Feb 8;67(3):1872-1887. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1205 mL | 10.6024 mL | 21.2049 mL | 53.0122 mL |
| 5 mM | 0.4241 mL | 2.1205 mL | 4.2410 mL | 10.6024 mL | |
| 10 mM | 0.2120 mL | 1.0602 mL | 2.1205 mL | 5.3012 mL | |
| 15 mM | 0.1414 mL | 0.7068 mL | 1.4137 mL | 3.5341 mL | |
| 20 mM | 0.1060 mL | 0.5301 mL | 1.0602 mL | 2.6506 mL | |
| 25 mM | 0.0848 mL | 0.4241 mL | 0.8482 mL | 2.1205 mL | |
| 30 mM | 0.0707 mL | 0.3534 mL | 0.7068 mL | 1.7671 mL | |
| 40 mM | 0.0530 mL | 0.2651 mL | 0.5301 mL | 1.3253 mL | |
| 50 mM | 0.0424 mL | 0.2120 mL | 0.4241 mL | 1.0602 mL | |
| 60 mM | 0.0353 mL | 0.1767 mL | 0.3534 mL | 0.8835 mL | |
| 80 mM | 0.0265 mL | 0.1325 mL | 0.2651 mL | 0.6627 mL | |
| 100 mM | 0.0212 mL | 0.1060 mL | 0.2120 mL | 0.5301 mL |
Powered by Bioz